The newly developed antibody 6H4 fragments (Fabs) specific to A? oligomers, encapsulated in the polymeric nanomicelles (PMs), were peripherally administrated to AD model mouse for 10 weeks. In mice that were administered anti-A?O 6H4 Fabs in the PMs, various toxic A? species (A? oligomers, A?42s, N3pE A?s, A?s with toxic conformer) and the presence of A? plaques with dense cores in the brain were significantly reduced. Additionally, suppression of the progression of pathological processes of AD was supported by the prevention of cognitive-behavioral decline in the spatial memory tests.
CREDIT: Department of Neurology and Neurological Science, TMDU
Researchers led by Tokyo Medical and Dental University (TMDU) find that antibody fragments encapsulated in nanomicelles cross the blood–brain barrier and reduce the levels of toxic A? species in the brain of an Alzheimer’s disease model mouse
Sometimes the best things in life come by chance, when we happen to be in the right place at the right time. Now, researchers from Japan have found a way to ensure that new medications are delivered to the right place in the body and at the right timepoint in disease progression, so that they have the best effect.
In a study published recently in the Journal of Nanobiotechnology, researchers led by Tokyo Medical and Dental University (TMDU) have revealed that a novel delivery system delivers treatment to where it is needed most in a mouse model of Alzheimer’s disease (AD).
AD is a common neurodegenerative disease that causes dementia. It is characterized by the accumulation of a protein called amyloid ? (A?) in the brain, and a number of different toxic forms of A? have been identified that impair brain function, notably A? oligomers (A?Os).
“Multiple clinical trials have attempted to use an anti-A? antibody to treat AD, but the results have been unsatisfactory,” says lead author of the study Akiko Amano. “One potential explanation for this is that the blood–brain barrier (BBB) prevents most full-length antibodies from entering the brain.”
To address this challenge, the researchers previously developed glucosylated (sugar-linked) polymeric nanomicelles (PMs), which are tiny, hollow balls that could successfully cross the BBB via transcytosis in mouse brain capillary endothelial cells; this process was mediated by glucose-transporter-1 and induced by an increase in blood glucose levels after the mice experienced fasting conditions. In this study, Takanori Yokota and colleagues filled PMs with fragments of an anti-A?O antibody, injected them into a mouse model of AD, and assessed the effects on the brain and on behavior.
“The results were very clear,” explains senior author Nobuo Sanjo. “Administration of anti-A?O antibody fragments through PMs significantly reduced the amounts of various toxic A? species. In addition, the A? plaques that did form were smaller and less dense than those seen in untreated mice.”
Next, the researchers analyzed the behavior of the mice and found that the mice treated with the antibody fragment-filled PMs had better learning and spatial memory than untreated mice. “Our findings suggest that delivering sufficient levels of antibodies to the brain using PMs can reduce toxic A? species and slow AD progression in mice,” says Amano.
Given that the failure of anti-A? antibodies to improve cognitive function in human clinical trials was likely because of an insufficient supply of the antibodies in the brain, PM-encapsulated antibody fragments could represent an effective way to prevent AD progression. In addition, new candidates for AD treatment that degrade toxic A?s and reduce their toxic effects could also be delivered to the brain using the same PM-based system.
Original Article: Transporting antibodies across the blood–brain barrier to treat Alzheimer’s disease
More from: Tokyo Medical and Dental University
The Latest Updates from Bing News
Go deeper with Bing News on:
Alzheimer’s disease
- At 54, Terry Kitay was diagnosed with early-onset Alzheimer's disease. This is her daughter's story
Terry was diagnosed with early-onset Alzheimer's disease in her 50s. This is her daughter's message to anyone going through the same experience.
- Gene thought to raise risk for Alzheimer’s may cause it
APOE4 gene is strongly associated with the disease and new study says the link may be stronger than previously thought.
- Dementia warning over lifestyle factors that increase risk of developing Alzheimer's disease, according to experts
Lifestyle factors have a significant influence on people's risk of dementia. Here, experts have identified 13 of the most common issues that impact people's chances of developing the condition.
- How exactly does a high-fat diet increase Alzheimer's risk?
New research in mouse models of Alzheimer's disease suggests that a high-fat diet causes molecular changes that disrupt brain health.
Go deeper with Bing News on:
PM-encapsulated antibody fragments
- Recombinant lipid-tagged antibody fragments as functional cell-surface receptors
To establish whether molecules other than scFv antibody fragments could be lipid-modified and inserted into cell membranes, we cloned the gene encoding human interleukin-2 (IL-2) into vector pLP2 ...
- Kirin gets grant for monoclonal antibody inhibiting ccr1 activation by ccl15
Kirin has been granted a patent for a monoclonal antibody that binds to human CCR1, inhibiting its activation by CCL15. The antibody can be used in therapeutic and diagnostic agents for CCR1-related ...
- Method created to better remove protein causing Alzheimer’s
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine, encapsulated fragments of an antibody that can attach itself to the protein and ...
- 'Grave Concern': Darjeeling BJP MLA Writes Letter To PM Modi In Blood Demanding Justice For Gorkhas
The assurance bestowed upon us by Hon'ble PM, encapsulated in the resounding pledge of "Gorkha ka Swapna, Mera Swapana," echoed in the BJP's Sankalpa Patra of 2009, 2014, and 2019, remains ...
- Recombinant antibody expression services and a novel antibody generation platform
Antibody Fragment Production Service: Generates high-purity antibodies in any format (scFv, VHH, Fab, etc.) at affordable prices. Bispecific Antibody Production Service: Produces recombinant bsAbs ...